Kirkwood JM - Search Results

1

Automatic multiparameter fluorescence imaging for determining lymphocyte phenotype and activation status in melanoma tissue sections.

Dow AI, Shafer SA, Kirkwood JM, Mascari RA, Waggoner AS. Dow AI, et al. Among authors: kirkwood jm. Cytometry. 1996 Sep 1;25(1):71-81. doi: 10.1002/(SICI)1097-0320(19960901)25:1<71::AID-CYTO8>3.0.CO;2-H. Cytometry. 1996. PMID: 8875056 Free article.

2

Molecular analysis of melanoma precursor lesions.

Wang Y, Rao U, Mascari R, Richards TJ, Panson AJ, Edington HD, Shipe-Spotloe JM, Donnelly SS, Kirkwood JM, Becker D. Wang Y, et al. Among authors: kirkwood jm. Cell Growth Differ. 1996 Dec;7(12):1733-40. Cell Growth Differ. 1996. PMID: 8959342

3

Gene therapy with autologous, interleukin 2-secreting tumor cells in patients with malignant melanoma.

Palmer K, Moore J, Everard M, Harris JD, Rodgers S, Rees RC, Murray AK, Mascari R, Kirkwood J, Riches PG, Fisher C, Thomas JM, Harries M, Johnston SR, Collins MK, Gore ME. Palmer K, et al. Among authors: kirkwood j. Hum Gene Ther. 1999 May 20;10(8):1261-8. doi: 10.1089/10430349950017941. Hum Gene Ther. 1999. PMID: 10365657 Clinical Trial.

4

Analysis of therapeutic and immunologic effects of R(24) anti-GD3 monoclonal antibody in 37 patients with metastatic melanoma.

Kirkwood JM, Mascari RA, Edington HD, Rabkin MS, Day RS, Whiteside TL, Vlock DR, Shipe-Spotloe JM. Kirkwood JM, et al. Cancer. 2000 Jun 15;88(12):2693-702. Cancer. 2000. PMID: 10870051 Clinical Trial.

5

High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696.

Kirkwood JM, Ibrahim J, Lawson DH, Atkins MB, Agarwala SS, Collins K, Mascari R, Morrissey DM, Chapman PB. Kirkwood JM, et al. J Clin Oncol. 2001 Mar 1;19(5):1430-6. doi: 10.1200/JCO.2001.19.5.1430. J Clin Oncol. 2001. PMID: 11230488 Clinical Trial.

6

Immunomodulatory effects of high-dose and low-dose interferon alpha2b in patients with high-risk resected melanoma: the E2690 laboratory corollary of intergroup adjuvant trial E1690.

Kirkwood JM, Richards T, Zarour HM, Sosman J, Ernstoff M, Whiteside TL, Ibrahim J, Blum R, Wieand S, Mascari R. Kirkwood JM, et al. Cancer. 2002 Sep 1;95(5):1101-12. doi: 10.1002/cncr.10775. Cancer. 2002. PMID: 12209697 Free article. Clinical Trial.

7

Analysis of two human monoclonal antibodies against melanoma.

Yeilding NM, Gerstner C, Kirkwood JM. Yeilding NM, et al. Among authors: kirkwood jm. Int J Cancer. 1992 Dec 2;52(6):967-73. doi: 10.1002/ijc.2910520623. Int J Cancer. 1992. PMID: 1459738

8

Preclinical studies, experimental therapeutics, and clinical management of advanced melanoma.

Kirkwood JM. Kirkwood JM. Curr Opin Oncol. 1992 Apr;4(2):368-79. doi: 10.1097/00001622-199204000-00020. Curr Opin Oncol. 1992. PMID: 1591310 Review.

9

Effects of interferon-gamma and tumour necrosis factor-alpha on the development of cytotoxic T lymphocytes in autologous mixed lymphocyte tumour cultures with human melanoma.

Roth AD, Hornicek FJ, Gerstner CG, Kirkwood JM. Roth AD, et al. Among authors: kirkwood jm. Clin Exp Immunol. 1991 Oct;86(1):163-72. doi: 10.1111/j.1365-2249.1991.tb05790.x. Clin Exp Immunol. 1991. PMID: 1833098 Free PMC article.

10

Interferons in melanoma.

Agarwala SS, Kirkwood JM. Agarwala SS, et al. Among authors: kirkwood jm. Curr Opin Oncol. 1996 Mar;8(2):167-74. doi: 10.1097/00001622-199603000-00015. Curr Opin Oncol. 1996. PMID: 8727310 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

600 results

Search Page